Sanofi eyeing pipeline deals ahead of Dupixent patent loss
Published . Updated .
This report does not map to a usual set of affected companies.
Directly affected
- SNY Sanofi
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Sanofi belongs to, so it often moves with news about it.
- NVS Novartis AG+1.3% 17d
Novartis AG is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- AZN AstraZeneca+2.1% 30d
AstraZeneca is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- NVO Novo Nordisk A/S-7.3% 30d
Novo Nordisk A/S is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- GSK Gsk-6.3% 10d
Gsk is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- ROIV Roivant Sciences+6.2% 7d
Roivant Sciences is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| SNY | -3.55% | -2.86% | base | after close | after close | after close | after close |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| NVSNo price data for this ticker | — | — | — | — | — | — | — |
| AZNNo price data for this ticker | — | — | — | — | — | — | — |
| NVONo price data for this ticker | — | — | — | — | — | — | — |
| GSKNo price data for this ticker | — | — | — | — | — | — | — |
| ROIVNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Sanofi eyeing pipeline deals ahead of Dupixent patent loss pharmaphorum
Source: pharmaphorum
Energy
| Company | When | Move | Status |
|---|---|---|---|
| SNY | three days earlier | -2.86% | final price |
| SNY | five days earlier | -3.55% | final price |
Congressional trades in the stocks in this story
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 64 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 50 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 60 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 65 days before publication. Filed 17 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Sanofi eyeing pipeline deals ahead of Dupixent patent loss” looks
12 out of 100
“Sanofi eyeing pipeline deals ahead of Dupixent patent loss” scores 12 out of 100. The score uses 1 sources.